Diffusion Pharmaceuticals Inc. (DFFN)

6.60 +0.06 (+0.92%) At close: 03:55PM EST

Diffusion Pharmaceuticals Inc.

300 East Main Street
Suite 201
Charlottesville, VA 22902
United States
434 220 0718
https://www.diffusionpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 16

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Robert J. Cobuzzi Jr., Ph.D.	Pres, CEO & Director	612.62k	N/A	1965
Mr. William Karl Hornung	Chief Financial Officer	450.68k	N/A	1969
Mr. William Robert Elder J.D.	Gen. Counsel & Corp. Sec.	338.36k	N/A	1983
Dr. Christopher D. Galloway M.D.	Chief Medical Officer	539.59k	N/A	1971
Dr. David Randolph Jones M.D.	Sr. Medical Advisor	N/A	N/A	1963
Ms. Suzanne Cassidy	Sr. Director & Head of Quality Assurance	N/A	N/A	N/A
Dr. Jennifer Llewelyn Ph.D.	Sr. Director & Head of CMC	N/A	N/A	N/A
Ms. Raven Jaeger M.S.	Chief Regulatory Officer	N/A	N/A	1978
Mr. Harry Cook	VP of Clinical Operations	N/A	N/A	N/A
Mr. Douglas Gravatt	Sr. Consultant for Manufacturing	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

Corporate Governance

Diffusion Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.